Hemab Therapeutics Holdings, Inc. (COAG) Stock Statistics & Valuation Metrics
Total Valuation
Hemab Therapeutics Holdings, Inc. has a market cap or net worth of $1.94B. The enterprise value is $1.26B.
- Market Cap
- $1.94B
- Enterprise Value
- $1.26B
Share Statistics
Hemab Therapeutics Holdings, Inc. has 46,712,116 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 46,712,116
- Owned by Insiders
- 25.74%
- Owned by Institutions
- 24.04%
Financial Efficiency
Hemab Therapeutics Holdings, Inc.’s return on equity (ROE) is 0.36 and return on invested capital (ROIC) is -37.82%.
- Return on Equity (ROE)
- 0.36
- Return on Assets (ROA)
- -0.33
- Return on Invested Capital (ROIC)
- -37.82%
- Return on Capital Employed (ROCE)
- -0.38
- Revenue Per Employee
- 0
- Profits Per Employee
- -1.08M
- Employee Count
- 59
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Hemab Therapeutics Holdings, Inc. is -31.64. Hemab Therapeutics Holdings, Inc.’s PEG ratio is -0.32.
- PE Ratio
- -31.64
- PS Ratio
- 0.00
- PB Ratio
- 2.75
- Price to FCF
- -43.79
- Price to Operating Cash Flow
- -28.22
- PEG Ratio
- -0.32
Income Statement
In the last 12 months, Hemab Therapeutics Holdings, Inc. had revenue of 0 and earned -63.91M in profits. Earnings per share was -2.33.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -70.12M
- Pretax Income
- -64.14M
- Net Income
- -63.91M
- EBITDA
- -69.81M
- Earnings Per Share (EPS)
- -2.33
Cash Flow
In the last 12 months, operating cash flow was -44.22M and capital expenditures 0, giving a free cash flow of -44.22M billion.
- Operating Cash Flow
- -44.22M
- Free Cash Flow
- -44.22M
- Free Cash Flow per Share
- -1.47
Dividends & Yields
Hemab Therapeutics Holdings, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -2.28%
- Earnings Yield
- -3.75%
Stock Price Statistics
- Beta
- -0.85
- 52-Week Price Change
- 21.91%
- 50-Day Moving Average
- 37.81
- 200-Day Moving Average
- 36.80
- Relative Strength Index (RSI)
- 67.19
- Average Volume (3m)
- 459.13K
Important Dates
Hemab Therapeutics Holdings, Inc. upcoming earnings date is ―, Before Open (Confirmed).
- Last Earnings Date
- Aug 11, 2026
- Next Earnings Date
- ―
- Ex-Dividend Date
- ―
Financial Position
Hemab Therapeutics Holdings, Inc. as a current ratio of 18.03, with Debt / Equity ratio of -0.69%
- Current Ratio
- 18.03
- Quick Ratio
- 18.03
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 1.24
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Hemab Therapeutics Holdings, Inc. has paid -227.00K in taxes.
- Income Tax
- -227.00K
- Effective Tax Rate
- 0.00
Enterprise Valuation
Hemab Therapeutics Holdings, Inc. EV to EBITDA ratio is -34.31, with an EV/FCF ratio of -38.44.
- EV to Sales
- 0.00
- EV to EBITDA
- -34.31
- EV to Free Cash Flow
- -38.44
- EV to Operating Cash Flow
- -38.44
Balance Sheet
Hemab Therapeutics Holdings, Inc. has $457.46M in cash and marketable securities with $1.03M in debt, giving a net cash position of $456.43M billion.
- Cash & Marketable Securities
- $457.46M
- Total Debt
- $1.03M
- Net Cash
- $456.43M
- Net Cash Per Share
- $9.77
- Tangible Book Value Per Share
- $15.09
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Hemab Therapeutics Holdings, Inc. is $62.50, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $62.50
- Price Target Upside
- 50.78% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 4
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- ―
Scores
- Smart Score
- 6
- AI Score
- ―
